Transferrin Inhibitors
2 drugsAbout Transferrin
Transferrin is a key protein responsible for iron transport throughout the body, maintaining iron homeostasis. It binds iron and delivers it to cells via receptor-mediated endocytosis.
Transferrin is a clinically relevant drug target for specific conditions related to iron imbalances. Currently, there is no genetic evidence data available linking Transferrin to specific diseases.
Transferrin is targeted by two FDA-approved small molecule drugs: IRON SUCROSE and MONOFERRIC, indicated for iron-related conditions. Novartis and PHARMACOSMOS are the key players in this space.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Endometrial Cancer with only 1 trials.
- phase2 represents biological uncertainty with 0% completion.
Top Drugs
Novartis and PHARMACOSMOS are the only two companies with approved Transferrin-targeting drugs.
Low market concentration suggests opportunities for new entrants with innovative approaches.
Drug Modality Landscape
Modalities
Routes of Administration
Transferrin is druggable by small molecules, though no oral formulations are currently approved.
Exploring alternative modalities like antibodies or peptides could provide differentiation.
Clinical Trials 94 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 20 | 16 | 1 | 3 | 94% |
| Phase 2 | 14 | 4 | 7 | 3 | 36% |
| Phase 3 | 33 | 22 | 2 | 9 | 92% |
| Phase 4 | 27 | 17 | 1 | 8 | 94% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
3 Phase 3 trials testing approved Transferrin drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Transferrin. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Drug Approval Timeline (2020 - 2025)
The first drug was approved in 2020, with the most recent approval in 2025, spanning 6 years.
Recent approvals suggest renewed interest, but further growth may be limited by market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 58 clinical trials targeting Transferrin.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities